全文获取类型
收费全文 | 1086篇 |
免费 | 25篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 38篇 |
妇产科学 | 6篇 |
基础医学 | 70篇 |
口腔科学 | 11篇 |
临床医学 | 72篇 |
内科学 | 207篇 |
皮肤病学 | 2篇 |
神经病学 | 20篇 |
特种医学 | 20篇 |
外科学 | 22篇 |
综合类 | 106篇 |
预防医学 | 68篇 |
药学 | 294篇 |
2篇 | |
中国医学 | 167篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 7篇 |
2022年 | 16篇 |
2021年 | 17篇 |
2020年 | 28篇 |
2019年 | 60篇 |
2018年 | 69篇 |
2017年 | 40篇 |
2016年 | 17篇 |
2015年 | 14篇 |
2014年 | 125篇 |
2013年 | 66篇 |
2012年 | 114篇 |
2011年 | 118篇 |
2010年 | 71篇 |
2009年 | 66篇 |
2008年 | 68篇 |
2007年 | 63篇 |
2006年 | 31篇 |
2005年 | 26篇 |
2004年 | 22篇 |
2003年 | 17篇 |
2002年 | 11篇 |
2001年 | 11篇 |
2000年 | 6篇 |
1999年 | 10篇 |
1998年 | 2篇 |
1997年 | 7篇 |
1996年 | 3篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1990年 | 1篇 |
1985年 | 1篇 |
1984年 | 3篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
排序方式: 共有1119条查询结果,搜索用时 15 毫秒
1.
2.
Wei Zhang Yuan-Yuan Li Qing-Hua Shang Lin Qi Mi-Mi Sun Gang Chen Yong An Jing-Xin Li Wang-Ping Jia Zhong-An Sun Hui-Bin Xu Qing-Mei Gao Li Tang Xiao-Wen Wang Ji-Yuan Zhang Yi-Ming Mu Fu-Sheng Wang 《Annals of hepatology》2022,27(6):100745
Introduction and ObjectivesHepatitis B surface antigen (HBsAg) clearance, indicating functional cure or resolved chronic hepatitis B (CHB), remains difficult to achieve via nucleos(t)ide analogue monotherapy. We investigated whether metformin add-on therapy could help achieve this goal in entecavir-treated patients with hepatitis B e antigen (HBeAg)-negative CHB.Patients and MethodsPatients with HBeAg-negative CHB who met eligibility criteria (entecavir treatment for > 12 months, HBsAg < 1000 IU/mL) were randomly assigned (1:1) to receive 24 weeks of either metformin (1000 mg, oral, once a day) or placebo (oral, once a day) add-on therapy. The group allocation was blinded for both patients and investigators. Efficacy and safety analyses were based on the intention-to-treat set. The primary outcome, serum HBsAg level (IU/mL) at weeks 24 and 36, was analysed using mixed models.ResultsSixty eligible patients were randomly assigned to the metformin (n = 29) and placebo (n = 31) groups. There was no substantial between-group difference in the HBsAg level at week 24 (adjusted mean difference 0.05, 95% confidence interval -0.04 to 0.13, p = 0.278) or week 36 (0.06, -0.03 to 0.15, p = 0.187), and no significant effect of group-by-time interaction on the HBsAg level throughout the trial (p = 0.814). The occurrence of total adverse events between the two groups was comparable (9 [31.0%] of 29 vs. 5 [16.1%] of 31, p = 0.227) and no patient experienced serious adverse events during the study.ConclusionAlthough it was safe, metformin add-on therapy did not accelerate HBsAg clearance in entecavir-treated patients with HBeAg-negative CHB. 相似文献
3.
4.
BackgroundAutoimmune hepatitis is a chronic inflammatory disease, the abnormal immunological function is the main pathogenesis. Interleukin-34 is a newly identified cytokine that shares the same receptor as colony stimulating factor-1.MethodsWe used interleukin-34 knockout and wild-type mice in a Con A-induced hepatitis model and cocultured RAW264.7 macrophage cells with interleukin-34. We then detected associated inflammatory cytokine and chemokine levels to elucidate the role of interleukin-34.ResultsIn this study, we found that the loss of interleukin-34 resulted in higher sensitivity to Con A-induced hepatitis. RAW264.7 macrophage cells were able to differentiate to the M2 phenotype upon interleukin-34 stimulation.ConclusionsWe conclude that interleukin-34 may protect the liver from Con A-mediated hepatitis by driving M2 macrophage polarization and suppressing inflammation. 相似文献
5.
Rie Shinoda Yasutaka Shinoda Kengo Ohashi Tomoko Matsuoka Tatsuya Hirose Tadashi Sugiyama Tomoaki Yoshimura 《Journal of infection and chemotherapy》2019,25(7):563-566
Teicoplanin formulations are marketed as antibiotic mixtures with several compounds that share the same core structure. Recent studies conducted in vitro have reported differences in the composition ratio of different teicoplanin products. In this retrospective study, we examined the trough blood concentration of the originator brand and a generic teicoplanin product. Target patients were retrospectively assigned to the originator (Targocid) or generic group. The groups were matched 1:1 using propensity scores. The initial trough blood concentration analysis identified 44 matches. In both groups, the median dosing day for the first measurements was 4, respectively. The initial trough blood concentration of the originator group was significantly higher (mean ± SD, 16.3 ± 4.5 mg/L) than that of the generic group (12.8 ± 4.7 mg/L; 95% CI, ?5.4 to ?1.6). A significant difference was observed in the frequency of serum creatinine elevation in the study of the frequency of adverse events using Common Terminology Criteria for Adverse Events (originator group, 41.9% vs generic group, 20.9%). In cases where discontinuation was necessary due to side effects, there were three patients in the originator group and one patient in the generic group. This study found that trough blood concentration differed between formulations. Therefore, correction might be necessary while monitoring drug concentration in the blood. Trough blood concentrations are used as surrogate markers for efficacy and safety, so further studies on differences in efficacy and safety between formulations are required. 相似文献
6.
7.
Jennifer A. Shulha Patricio Escalante John W. Wilson 《Mayo Clinic proceedings. Mayo Clinic》2019,94(8):1567-1581
Nontuberculous mycobacteria (NTM) comprise a heterogeneous group of organisms, with only a small subset known to cause disease in humans. Although NTM infection is not a reportable disease, both the increasing clinical recognition and recent advancements in laboratory diagnostic capabilities of NTM infections in immunocompromised and immunocompetent patients are rapidly evolving. We reviewed antimicrobial agents used to treat the most frequently encountered NTM infections and examined optimized drug dosing strategies, toxicity profiles, drug-drug interactions, and the role of therapeutic drug monitoring. Antimicrobial susceptibility testing and patient monitoring on therapy were also examined. We used PubMed to review the published literature on the management of select NTM pathogens, the common syndromes encountered since 2000, and select pharmacokinetic principles of select antimicrobial agents used since 1990. We included select clinical trials, systematic reviews, published guidelines, and observational studies when applicable. The prolonged duration and the necessity for combination therapy for most forms of NTM disease can be problematic for many patients. A multidisciplinary care team that includes pharmacy engagement may help increase rates of optimal patient tolerability and successful treatment completion. 相似文献
8.
9.
10.
目的 探讨腺苷蛋氨酸联合恩替卡韦对胆汁淤积型乙型病毒性肝炎(乙肝)的预后影响。方法 选择2016年9月— 2019年2月在开封市中心医院收治的胆汁淤积型乙肝患者172例。根据治疗方法的不同将患者分为对照组(72例)和观察组(100例)。对照组口服恩替卡韦分散片,0.5 mg/d。观察组在对照组治疗的基础上使用注射用丁二磺酸腺苷蛋氨酸,1 g/d。两组均治疗观察8周。观察两组患者的临床疗效,同时比较两组患者的肝功能指标、乙肝病毒的脱氧核糖核酸(HBVDNA)阴转情况和不良反应发生情况。结果 治疗后,观察组的总有效率为97.0%,显著高于对照组的80.6%(P<0.05)。两组治疗后的血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)水平均显著低于治疗前(P<0.05),且观察组各肝功能指标水平显著低于对照组(P<0.05)。治疗后,观察组的HBV-DNA转阴率为99.0%,显著高于对照组的90.3%(P<0.05)。两组治疗期间的不良反应发生率比较差异无统计学意义。结论 腺苷蛋氨酸联合恩替卡韦治疗胆汁淤积型乙肝能提高HBV-DNA转阴率与治疗效果,促进患者肝功能的改善,且不会增加不良反应,具有一定的临床推广应用价值。 相似文献